Limits...
Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation.

Huo ZJ, Wang SJ, Wang ZQ, Zuo WS, Liu P, Pang B, Liu K - Cancer Sci. (2015)

Bottom Line: Pharmacokinetic data suggested that nanoparticles could significantly enhance the blood circulation time of LPT by reducing the uptake by a reticuloendothelial system (RES).Importantly, PLPT significantly reduced the tumor burden of cancerous mice and effectively controlled the tumor cell proliferation.TUNEL assay further showed a greater apoptosis of tumor tissues in the PLPT treated mice group.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Disease Center, Shandong Cancer Hospital & Institute, Jinan, China.

No MeSH data available.


Related in: MedlinePlus

Tumor growth curve of the xenograft nude mice bearing MCF-7 cell after intravenous administration of formulations (control (black), blank NP (red), free lapatinib (LPT) (green), and polymer-lipid containing LPT (PLPT) (blue). (a) Tumor volume and (b) body weight of mice. ***P < 0.001 is the statistical difference between release at PLPT and control.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4637996&req=5

fig07: Tumor growth curve of the xenograft nude mice bearing MCF-7 cell after intravenous administration of formulations (control (black), blank NP (red), free lapatinib (LPT) (green), and polymer-lipid containing LPT (PLPT) (blue). (a) Tumor volume and (b) body weight of mice. ***P < 0.001 is the statistical difference between release at PLPT and control.

Mentions: Inspired by the excellent in vitro antitumor efficacy and systemic performance of PLPT, we have further evaluated the antitumor efficacy of different formulations in MCF-7 cancer cell bearing xenograft tumor model. As seen (Fig.7a), untreated mice group as well as mice treated with blank nanoparticles did not have any effect on the tumor growth (tumor volume) and continuously proliferated during the entire study period. In contrast, groups treated with free LPT and PLPT significantly delayed and inhibited the tumor growth. At the end of 21 days, tumor volumes of mice treated with free LPT stood at approximately 1500 mm3, while tumor volumes of untreated mice group were approximately 2500 mm3. Importantly, PLPT showed a low tumor volume of approximately 700 mm3 at the end of 21 days. Consequently, body weight was noted to examine the safety profile of individual formulations (Fig.7b). As seen, the body weights of all the mice groups gradually increased indicating that none of the formulations were toxic to the animals. The excellent tumor inhibitory effect along with no systemic side-effects could be advantageous to cancer targeting.


Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation.

Huo ZJ, Wang SJ, Wang ZQ, Zuo WS, Liu P, Pang B, Liu K - Cancer Sci. (2015)

Tumor growth curve of the xenograft nude mice bearing MCF-7 cell after intravenous administration of formulations (control (black), blank NP (red), free lapatinib (LPT) (green), and polymer-lipid containing LPT (PLPT) (blue). (a) Tumor volume and (b) body weight of mice. ***P < 0.001 is the statistical difference between release at PLPT and control.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4637996&req=5

fig07: Tumor growth curve of the xenograft nude mice bearing MCF-7 cell after intravenous administration of formulations (control (black), blank NP (red), free lapatinib (LPT) (green), and polymer-lipid containing LPT (PLPT) (blue). (a) Tumor volume and (b) body weight of mice. ***P < 0.001 is the statistical difference between release at PLPT and control.
Mentions: Inspired by the excellent in vitro antitumor efficacy and systemic performance of PLPT, we have further evaluated the antitumor efficacy of different formulations in MCF-7 cancer cell bearing xenograft tumor model. As seen (Fig.7a), untreated mice group as well as mice treated with blank nanoparticles did not have any effect on the tumor growth (tumor volume) and continuously proliferated during the entire study period. In contrast, groups treated with free LPT and PLPT significantly delayed and inhibited the tumor growth. At the end of 21 days, tumor volumes of mice treated with free LPT stood at approximately 1500 mm3, while tumor volumes of untreated mice group were approximately 2500 mm3. Importantly, PLPT showed a low tumor volume of approximately 700 mm3 at the end of 21 days. Consequently, body weight was noted to examine the safety profile of individual formulations (Fig.7b). As seen, the body weights of all the mice groups gradually increased indicating that none of the formulations were toxic to the animals. The excellent tumor inhibitory effect along with no systemic side-effects could be advantageous to cancer targeting.

Bottom Line: Pharmacokinetic data suggested that nanoparticles could significantly enhance the blood circulation time of LPT by reducing the uptake by a reticuloendothelial system (RES).Importantly, PLPT significantly reduced the tumor burden of cancerous mice and effectively controlled the tumor cell proliferation.TUNEL assay further showed a greater apoptosis of tumor tissues in the PLPT treated mice group.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Disease Center, Shandong Cancer Hospital & Institute, Jinan, China.

No MeSH data available.


Related in: MedlinePlus